REVERSE MERGER (Pro-forma Disclosures) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Business Acquisition [Line Items]
Net sales	$ 712		$ 907
Net loss available to common stockholders	$ (5,953)		$ (2,778)
Loss per common share (in dollars per share)	$ (0.47)		$ (0.42)
Transgenomics
Business Acquisition [Line Items]
Net sales	$ 712	$ 907
Net loss available to common stockholders	$ (5,953)	$ (2,778)
Loss per common share (in dollars per share)	$ (0.47)	$ (0.42)